NCT07156045招募中1 期
Clinical Study on the Safety and Efficacy of Anti-PSMA CAR NK Cells in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2025年9月1日最近更新:
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Occurrence of treatment related adverse events as assessed by CTCAE v5.0
研究概览
简要总结
At present, no cell drug with an indication for mCRPC has been approved for marketing in China, and there is no scholar to fight against it PSMA-CAR-NK cell therapy CRPC was reported in a study. Based on the previous basic research, our company has developed CAR-NK cell injection, hoping to further evaluate its safety, tolerability and preliminary efficacy in the treatment of mCRPC patients in clinical studies, and provide new possibilities for the selection of clinical treatment strategies
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •To enter the trial, subjects had to meet all of the following eligibility criteria:
- •diagnosed metastatic castration-resistant prostate cancer (mCRPC);
- •Castration level of serum testosterone (< 50 ng/dL or < 1.7 nmol/L);
- •Positive expression of PSMA;
- •According to the definition of CRPC in the Guidelines for the Diagnosis and Treatment of Prostate Cancer (2022 edition), the disease still progresses after castration and meets any of the following criteria:
- •A.According to the increase in PSA level, there should be 3 consecutive increases in PSA at least 1 week apart (the increase in PSA is more than 50% of the minimum value, and PSA > 2 ng/mL); B.Progression of bone disease as defined by PCWG3, defined as the presence of 2 or more new lesions on bone scan; C.CT or MRI results suggested measurable metastasis (lymph node short diameter > 15 mm was defined as lymph node metastasis as assessed by RECIST 1.1);
- •Expected survival time ≥6 months;
- •Toxicity of any previous treatment had recovered to ≤ grade 1 at the time of enrollment (except hair loss and hearing loss);
- •ECOG score of patients 0-2;
- •Patients voluntarily participated and signed the informed consent, and followed the trial treatment plan and visit plan.
排除标准
- •Subjects who meet one of the following conditions will not be enrolled in the trial:
- •Previous recipients of other cell therapy products, such as dendritic cells (DC), multiple cytokine-induced killer cells (CIK), T cells, natural killer cells (NK), chimeric antigen receptor T-cell immunotherapy (CAR-T), etc.;
- •Patients with a history of biological macromolecule drug allergy;
- •Abnormal function of major organs:
- •A. Neutrophil count (ANC) < 1.5×109/L; Platelet count (Plt) < 100×109/L; Hemoglobin (Hb) < 9 g/dL; B. Liver function: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≥2.5×ULN (≥5×ULN for liver metastases); C. Renal function: serum creatinine (Cr) ≥1.5×ULN; D. Prothrombin time (PT) > 15 s, activated partial thrombin time (APTT) was prolonged or shortened by more than 10 s (normal reference value 23 s-37 s), or international normalized ratio (INR) > 1.7; E. Pulmonary function: Severe respiratory diseases (active pulmonary tuberculosis, chronic obstructive pulmonary disease, interstitial lung disease, etc.)
- •Previous treatment with any PSMA-targeted therapy;
- •active autoimmune diseases (including connective tissue disease, uveitis, sarcoidosis, inflammatory bowel disease, or multiple sclerosis) or need long-term immunosuppressive therapy of severe autoimmune disease (screening clinic within six weeks before any immunosuppressive therapy), or by the researchers determine in 3 months will be recurrence of subjects;
- •have had other malignancies other than prostate cancer (other than basal or squamous cell skin cancer) in the past 5 years that are currently clinically significant and require intervention;
- •Any active (viral, bacterial, fungal) infection currently being treated or any infection requiring intravenous antibiotics for 7 or more days or intervals during the past 6 weeks or any active infection requiring oral antibiotics during the past 1 week;
- •untreated chronic active hepatitis B, or chronic hepatitis B virus carriers with HBV DNA≥1000 copies /mL, or active hepatitis C patients;
- •Patients who have participated in other clinical trials and used study drugs within 3 months;
- •Effective contraceptive measures cannot be adopted ;
- •In the opinion of the investigator, there are other factors that are not suitable for inclusion or affect the participant's participation or completion of the study.
研究组 & 干预措施
Experimental group
Experimental
干预措施: anti-PSMA CAR-NK (Biological)
结局指标
主要结局
Occurrence of treatment related adverse events as assessed by CTCAE v5.0
时间窗: Baseline to 1 year post infusion
Defined as \>= Grade 3 signs/symptoms, laboratory toxicities, and clinical events) that are possibly, likely, or definitely related to study treatment
次要结局
- The pharmacokinetic analysis of Anti-PSMA CAR-NK Cell(D0, D1, D3, D7, D8, D10, D14, D15, D17, D28±1, D60±2, D120±2, D180±7, D270±7, and D365±7 post infusion)
- The pharmacodynamics analysis of Anti-PSMA CAR NK Cell(Baseline to infusion date, D28±1, D60±2, D120±2, D180±7, D270±7, 和 D365±7)
- The proportion of patients with a decrease in PSA levels from baseline(Baseline to D28±1, D60±2, D120±2, D180±7, D270±7, and D365±7 post infusion)
- Time to clinical progression(Baseline to D28±1, D60±2, D120±2, D180±7, D270±7, and D365±7 post infusion)
- Progression-free survival (PFS) after Anti-PSMA CAR NK Cell infusion(Baseline to 1 year post infusion)
- The pharmacodynamics analysis of Anti-PSMA CAR NK Cell(Baseline to infusion date, D28±1, D60±2, D120±2, D180±7, D270±7, and D365±7)
研究者
XINGNIANZENG
Vice President of the Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Safety and Pharmacokinetics of Jin Fu Kang in Comb w/Docetaxel for Patients w/Non-Small Cell Lung CancerNon-Small Cell Lung CancerNCT00260026Memorial Sloan Kettering Cancer Center20
进行中（未招募）
2 期
Safety and Efficacy Study of GB001 Recombinant Peptide Spray in Subjects With Mild Recurrent Aphthous UlcersHealthyNCT06429566Zhejiang Echon Biopharm Limited120
进行中（未招募）
1 期
Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal CancerColorectal CancerNCT06464692AbbVie31
尚未招募
不适用
Multi-center Clinical Study on Chinese Medicine Combined with Assisted Reproduction Technique in the Treatment of InfertilityITMCTR2000004138Shanghai Traditional Chinese Medicine Hospital
招募中
1 期
Clinical Study for Traditional Chinese Medicine Combined With Western Medicine in Treatment of Novel Coronavirus Pneumonia (COVID-19)ITMCTR2000003003Shanghai University of TCM